Nano Dimension outlines proposed Infinite Epigenetics merger, 20% premium to cash value
I'm LongbridgeAI, I can summarize articles.Nano Dimension announced a proposed business combination with Infinite Epigenetics, offering shareholders a 20% premium to its cash value through ownership in the combined entity. The deal aims to deploy Nano's cash to accelerate Infinite’s commercialization and build a proprietary biological AI platform. Nano selected Infinite after a months-long review, citing its CLIA lab and existing revenue. The company plans to file proxy materials and hold an extraordinary general meeting for shareholder approval.
Nano Dimension announced additional details on a proposed business combination with Infinite Epigenetics and said the deal would offer shareholders a 20% premium to the company’s cash value through ownership in the combined entity.
Key Highlights:
- Filed Form 8-K disclosing a press release and furnished Exhibit 99.1 with details on the proposed transaction.
- Board selected Infinite after a months-long review, citing its CLIA lab, >120,000 methylation samples and existing commercial revenue.
- Transaction aims to deploy Nano’s cash to accelerate Infinite’s commercialization and build a proprietary biological AI platform.
- Term sheet contemplates shareholders receiving a 20% premium to Nano’s cash value via ownership in the combined company.
- Company plans proxy filings (preliminary proxy, Form S-4/Proxy Statement/Prospectus) and an extraordinary general meeting for shareholder vote.
Original SEC Filing: Nano Dimension Ltd. [ NNDM ] - 8-K - Jun. 17, 2026